Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2023 September;65(3) > Panminerva Medica 2023 September;65(3):327-34

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Panminerva Medica 2023 September;65(3):327-34

DOI: 10.23736/S0031-0808.21.04573-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Paclitexel versus sirolimus-coated balloon in the treatment of coronary instent restenosis

Carlo BRIGUORI 1 , Gabriella VISCONTI 1, Marco GOLINO 1, Amelia FOCACCIO 1, Mario SCARPELLI 1, Silvia NUZZO 2, Giuseppe BIONDI-ZOCCAI 1, 3

1 Unit of Interventional Cardiology, Mediterranea Cardiocentro, Naples, Italy; 2 IRCCS SDN, Naples, Italy; 3 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy



BACKGROUND: Few studies compared paclitaxel-coated balloon (PCB) versus sirolimus-coated balloon (SCB) in the treatment of drug-eluting stent (DES) instent restenosis (ISR).
METHODS: Between November 5, 2009, and October 14, 2020, in our center 212 patients with first DES-ISR were treated with PCB (Restore®; Cardionovum GmbH, Bonn, Germany), whereas 230 patients were treated with SCB (Devoir®; MINVASYS SAS, Gennevilliers, France). Following a propensity matching, 186 patients were included into PCB group (PCB group), and in the SCB group (SCB group). The primary purpose of the study was the 1-year target lesion failure (TLF) rate, including cardiac death, target vessel-related myocardial infarction, and repeated target lesion or target vessel revascularization.
RESULTS: Procedural success occurred in all cases. Fully optimal predilation (that is, balloon-to-stent ratio >0.91, time of DCB inflation >60 sec, and residual percent diameter stenosis after lesion preparation <20%) was observed more often in the SCB group (126 [68%] patients versus 106 [57%] patients; P=0.042). One-year TLF occurred in 29 (15.5%) patients in the SCB group and in 32 (17%) patients in the PCB group (OR=1.12 [0.65-1.95]; P=0.78). By logistic Cox regression analysis fully optimal predilation (OR=0.06; 95% CI: 0.01-0.21; P<0.001) but not DCB type (OR=0.74; 95% CI: 0.41-1.31; P=0.29) was independent predictor of 1-year TLF.
CONCLUSIONS: The current study suggests that 1-year TLF is not statistically and clinically different in patients with DES ISR treated with a PCB and a SCB.


KEY WORDS: Angioplasty, balloon; Drug-eluting stents; Coronary restenosis

top of page